EUVIMEDEUVIMED entdecken
Open Access

TRBC1-targeting antibody–drug conjugates for the treatment of T cell cancers

Tushar D Nichakawade iD, Jiaxin Ge iD, Brian J Mog iD, Bum Seok Lee, Alexander H Pearlman iD, Michael S Hwang, Sarah R DiNapoli, Nicolas Wyhs, Nikita Marcou iD, Stephanie Glavaris, Maximilian F Konig iD, Sandra B Gabelli iD und 15 weitere

Nature · 11.04.2024 · 628 (8007) · 416-423

DOI: 10.1038/s41586-024-07233-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nature, online erschienen am 27.03.2024. Verfasst von Tushar D Nichakawade und 26 weiteren Autor:innen. Beteiligte Einrichtung: Ludwig Center and Lustgarten Laboratory, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD, U…. Hauptthemen laut MEDLINE: Immunoconjugates, Leukemia, T-Cell, Lymphoma, T-Cell, Receptors, Antigen, T-Cell, alpha-beta. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NCI NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody and chimeric antigen receptor (CAR) T cell-mediated targeted therapies have improved survival in patients with solid and haematologic malignancies1-9. Adults with T cell leukaemias and lymphomas, collectively called T cell cancers, have short survival10,11 and lack such targeted therapies. Thus, T cell cancers particularly warrant the development of CAR T cells and antibodies to improve patient outcomes. Preclinical studies showed that targeting T cell receptor β-chain constant region 1 (TRBC1) can kill cancerous T cells while preserving sufficient healthy T cells to maintain immunity12, making TRBC1 an attractive target to treat T cell cancers. However, the first-in-human clinical trial of anti-TRBC1 CAR T cells reported a low response rate and unexplained loss of anti-TRBC1 CAR T cells13,14. Here we demonstrate that CAR T cells are lost due to killing by the patient's normal T cells, reducing their efficacy. To circumvent this issue, we developed an antibody-drug conjugate that could kill TRBC1+ cancer cells in vitro and cure human T cell cancers in mouse models. The anti-TRBC1 antibody-drug conjugate may provide an optimal format for TRBC1 targeting and produce superior responses in patients with T cell cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesLeukemia, T-CellLymphoma, T-CellReceptors, Antigen, T-Cell, alpha-betaT-LymphocytesAnimalsFemaleHumansMiceImmunotherapy, AdoptiveReceptors, Chimeric AntigenXenograft Model Antitumor Assays

Substanzen

ImmunoconjugatesReceptors, Antigen, T-Cell, alpha-betaReceptors, Chimeric AntigenTRBC1 protein, human

Autor:innen und Institutionen

  • Ludwig Center and Lustgarten Laboratory, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Howard Hughes Medical Institute, Chevy Chase, MD, USA.
  • Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA.
  • Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA.
  • Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, USA.
  • Genentech, San Francisco, CA, USA.

ORCID-Profile: Tushar D Nichakawade, Jiaxin Ge, Brian J Mog, Alexander H Pearlman, Nikita Marcou, Maximilian F Konig, Sandra B Gabelli, Drew M Pardoll, Nickolas Papadopoulos, Chetan Bettegowda, Shibin Zhou, Bert Vogelstein, Suman Paul

Förderung

  • NIGMS NIH HHS
  • NCI NIH HHS
  • NIAID NIH HHS

Zitieren

APA

Nichakawade, T. D., Ge, J., Mog, B. J., Lee, B. S., Pearlman, A. H., Hwang, M. S., DiNapoli, S. R., Wyhs, N., Marcou, N., Glavaris, S., Konig, M. F., Gabelli, S. B., Watson, E., Sterling, C., Wagner-Johnston, N., Rozati, S., Swinnen, L., Fuchs, E., Pardoll, D. M., …, & Paul, S. (2024). TRBC1-targeting antibody–drug conjugates for the treatment of T cell cancers. Nature, 628(8007), 416-423. https://doi.org/10.1038/s41586-024-07233-2

Vancouver

Nichakawade TD, Ge J, Mog BJ, Lee BS, Pearlman AH, Hwang MS, et al. TRBC1-targeting antibody–drug conjugates for the treatment of T cell cancers. Nature. 2024;628(8007):416-423. doi:10.1038/s41586-024-07233-2

BibTeX
@article{Nichakawade2024,
  author = {Nichakawade, Tushar D and Ge, Jiaxin and Mog, Brian J and Lee, Bum Seok and Pearlman, Alexander H and Hwang, Michael S and DiNapoli, Sarah R and Wyhs, Nicolas and Marcou, Nikita and Glavaris, Stephanie and Konig, Maximilian F and Gabelli, Sandra B and Watson, Evangeline and Sterling, Cole and Wagner-Johnston, Nina and Rozati, Sima and Swinnen, Lode and Fuchs, Ephraim and Pardoll, Drew M and Gabrielson, Kathy and Papadopoulos, Nickolas and Bettegowda, Chetan and Kinzler, Kenneth W and Zhou, Shibin and Sur, Surojit and Vogelstein, Bert and Paul, Suman},
  title = {TRBC1-targeting antibody–drug conjugates for the treatment of T cell cancers},
  journal = {Nature},
  year = {2024},
  volume = {628},
  number = {8007},
  pages = {416--423},
  doi = {10.1038/s41586-024-07233-2}
}
Kostenlos starten →